Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon crossover study of acid pocket and reflux after a high-fat meal
2012-000678-44Phase 2Terminated
- Sponsor
- Reckitt
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Gaviscon Double Action and gaviscon advance in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Reckitt. Primary endpoint: Percentage of time with pH below 4 at 5 cm above the squamocolumnar junction over 2 hours. Started Jun 2012; status: terminated.
02
Drugs
Gaviscon Double Actiongaviscon advance
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2012-000678-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000678-44.